For weight management, reduced dosing frequency may diminish the appetite-suppressing effects and lead to weight regain
As healthcare systems focus on preventive measures and effective treatment options for these chronic conditions, the demand for GLP-1 receptor agonists is expected to grow, driving market expansion
Is my data private
In the context of GLP-1R agonists, GLP-1-expressing NTS neurons project to the VTA [98], and administration of exendin-4 into this brain region reduces food intake [98,99,100] and the motivation to obtain a food reward [99, 100] without causing aversion [98,99,100]
Next, we had a small sample size ( n = 14) in the DLPFC which made it difficult to make comparisons between regions (ACC vs
Less emotionally responsive